Accessibility Menu
Cosciens Biopharma logo

Cosciens Biopharma(OTC) AEZS

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-98%
1 Year-45%
1 Month-3%
N/A
Cosciens Biopharma last closing stock price
MetricPriceDate
Last closeUSD 4.982026-08-31
Cosciens Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.49%USD 5.162026-08-24
1 month-3.11%USD 5.142026-07-31
3 month-10.27%USD 5.552026-06-02
Year to date-19.42%USD 6.182025-12-31
1 year-45.39%USD 9.122025-08-29
3 year-83.47%USD 30.122023-09-01
5 year-97.73%USD 218.942021-09-01
Since inception-100%USD 1,912,484.702000-05-10

Cosciens Biopharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.47M

Net Income (TTM)

-$5.24M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 13, 2024

AEZS News

Tackling Cancer: Your Best Investing Ideas

Sean WilliamsJun 1, 2013
Endometrial cancer

Tackling Cancer: Endometrial Cancer's Biggest Current and Upcoming Players

Sean WilliamsMay 11, 2013

Aeterna Zentaris Names New CEO

Eric VolkmanApr 15, 2013

This Week in Biotech

Sean WilliamsMar 16, 2013

Breakdown of This Biotech Massacre

Dave WilliamsonMar 11, 2013

Will the Feuerstein-Ratain Rule Hold in 2013?

Maxx ChatskoJan 18, 2013
oprhan drugs

Do Orphan Drug Developers Belong in Your Portfolio?

Sean WilliamsJan 15, 2013

This Week in Biotech

Sean WilliamsJan 5, 2013
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

Aeterna Zentaris Inc. is a specialized biopharmaceutical company focused on developing and commercializing therapeutic drugs and diagnostic tests. The company’s flagship product, macimorelin, is an innovative treatment for growth hormone deficiency, with ongoing research into oncology applications.

Products and Services
  • Macimorelin, an orally administered ghrelin receptor agonist
  • Collaborative development of a COVID-19 vaccine
  • Research on treatments for neuromyelitis optica spectrum disorder and Parkinson's disease
Growth Outlook
  • Recent partnerships enhance product development capabilities
  • Ongoing clinical trials may expand market opportunities
  • Strong cash position supports future research initiatives
Financial Highlights
  • Q2 2024 revenue of $2.34 million, showing growth from previous quarters
  • Cash and cash equivalents of $27.8 million as of June 30, 2024
  • Current ratio of 5.57 indicates strong liquidity position
Aeterna Zentaris Inc. operates in the biotechnology sector, leveraging its expertise to address unmet medical needs. The company has established significant collaborations, which may enhance its research and development capabilities. The recent revenue growth reflects the potential for increased market penetration, while a robust cash position provides a solid foundation for future initiatives. The current ratio indicates a strong liquidity position, allowing the company to navigate operational challenges effectively. Overall, Aeterna Zentaris presents an intriguing opportunity for investors interested in the biopharmaceutical landscape.
AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

Headquarters

Summerville, SC 29486, US

AEZS Financials

Key Financial Metrics (TTM)

Gross Margin

45.38%

Operating Margin

-60.97%

Net Income Margin

-57.58%

Return on Equity

-48.74%

Return on Capital

-75.20%

Return on Assets

-25.32%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$778.89K

Operating Income

-$20.96M

EBITDA

-$12.22M

Operating Cash Flow

-$14.55M

Capital Expenditure

-$176.10K

Free Cash Flow

-$14.72M

Cash & ST Invst.

$27.80M

Total Debt

$1.69M

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,640,0007.2%
20232023-12-31USD 7,143,00026.6%
20242024-12-31USD 9,587,00034.2%
20252025-12-31USD 7,498,000-21.8%
Cosciens Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-99.9%
Q42023-12-314044.8%
Q12024-03-31-96.8%
Q22024-06-3058589.1%
Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -56.16157.1%
20232023-12-31USD -22.64-59.7%
20242024-12-31USD -17.79-21.4%
20252025-12-31USD -9.82-44.8%
Cosciens Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3099.6%
Q42023-12-31-46300.0%
Q12024-03-31-2.2%
Q22024-06-3086.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$2.34M

+4.1%

Gross Profit

$819.00K

-61.1%

Gross Margin

35.04%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

12

N/A

Net Income

-$1.42M

+43.5%

EBITDA

-$3.27M

-218.5%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$27.80M

-34.1%

Total Debt

$1.69M

+633.5%

Accounts Receivable

$1.36M

+38.9%

Inventory

$3.06M

+3184.9%

Long Term Debt

$1.28M

-58.7%

Short Term Debt

$407.00K

-30.2%

Return on Assets

-25.32%

N/A

Return on Invested Capital

-30.43%

N/A

Free Cash Flow

-$1.55M

+64.0%

Operating Cash Flow

-$1.39M

+67.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PIRSPieris Pharmaceuticals, Inc.
$13.60-15.58%
CYCCCyclacel Pharmaceuticals, Inc.
$6.37-5.98%
ACERAcer Therapeutics Inc.
$0.66-17.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About AEZS

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at N/A per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between N/A and N/A.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $1.96M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $5.28M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services